The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Abstract
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an antibody-targeted chemotherapy agent, in patients with CD33-positive acute myeloid leukemia (AML) in untreated first relapse. PATIENTS AND METHODS: The study population comprised 142 patients with AML in first relapse with no history of an antecedent hematologic disorder and a median age of 61 years. All patients received Mylotarg as a 2-hour intravenous infusion, at a dose of 9 mg/m 2, at 2-week intervals for two doses. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS: Thirty percent of patients treated with Mylotarg obtained remission as characterized by 5% or less blasts in the marrow, recovery of neutrophils to at least 1,500/μL, and RBC and platelet transfusion independence. Although patients treated with Mylotarg had relatively high incidences of myelosuppression, grade 3 or 4 hyperbilirubinemia (23%), and elevated hepatic transaminase levels (17%), the incidences of grade 3 or 4 mucositis (4%) and infections (28%) were relatively low. There was a low incidence of severe nausea and vomiting (11%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Many patients received Mylotarg on an outpatient basis (38% and 41% of patients for the first and second doses, respectively). Among the 142 patients, the median total duration of hospitalization was 24 days; 16% of patients required 7 days of hospitalization or less. CONCLUSION: Administration of the antibody-targeted chemotherapy agent Mylotarg to patients with CD33-positive AML in first relapse induces complete remissions with what appears to be a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Self-citationWinkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Clift, R., Buckner, C., Appelbaum, F., Bearman, S., Petersen, F., Fisher, L., Anasetti, C., Beatty, P., Bensinger, W., & Doney, K. (1990) · Blood · doi:10.1182/blood.v76.9.1867.1867 · Cited by 585
Self-citationSievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Self-citationA monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., & Schlossman, S. F. (1984) · Leukemia Research · doi:10.1016/0145-2126(84)90001-8 · Cited by 403
Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
REES, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92674-7 · Cited by 320
Expression of normal myeloid-associated antigens by acute leukemia cells
Dinndorf, P., Andrews, R., Benjamin, D., Ridgway, D., Wolff, L., & Bernstein, I. (1986) · Blood · doi:10.1182/blood.v67.4.1048.1048 · Cited by 229
Self-citationScheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Feirt, N., Finn, R. D., Clarkson, B. D., & Gee, T. S. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.478 · Cited by 224
Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., Ueda, T., Minami, S., MORISHIMA, Y., & Saito, Y. (1994) · Blood · doi:10.1182/blood.v83.8.2086.2086 · Cited by 153
Hiddemann, W., Martin, W. R., Sauerland, C., Heinecke, A., & Büchner, T. (1990) · PubMed · Cited by 107
Monoclonal antibody-based therapies for hematologic malignancies.
Multani, P. S., & Grossbard, M. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3691 · Cited by 73
Davis, C. L., Rohatiner, A. Z. S., Lim, J., Whelan, J., Oza, A. M., AMESS, J. A. L., Love, S., Stead, E., & Lister, T. A. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb04664.x · Cited by 39
Results of Therapy for Acute Myeloid Leukemia in First Relapse
Angelov, L., Brandwein, J. M., Baker, M. A., Scott, J. G., Sutton, D., & Keating, A. (1991) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199109064874 · Cited by 20
Timed sequential chemotherapy for advanced acute myeloid leukemia
Archimbaud, E., Leblond, V., Fenaux, P., Dombret, H., Cordonnier, C., Dreyfus, F., Cony‐Makhoul, P., Tilly, H., Troussard, X., Auzanneau, G., et al. (1996) · Hematology and Cell Therapy · doi:10.1007/s00282-996-0161-2 · Cited by 19
Self-citation
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Metadata
- Authors
- Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., Berger, M. S., Eten, C. B., Loken, M. R., van Dongen, J. J. M., Bernstein, I. D., Appelbaum, F. R., & for the Mylotarg Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2001-07-01
- Volume
- 19
- Issue
- 13
- Pages
- 3244-3254
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1842764967
- Cited by
- 899
- References
- 16
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.